Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Enlivex ( (ENLV) ) has shared an update.
Enlivex Ltd. is a Nasdaq-listed quality longevity company based in Israel that is advancing Allocetra™, a clinical-stage immunotherapy for aging-related inflammatory conditions, primarily age-related osteoarthritis. The company also operates a prediction markets treasury strategy built around the RAIN token of the Rain protocol on Arbitrum, combining biotech development with exposure to decentralized prediction markets.
On May 15, 2026, Enlivex reported that it received a Nasdaq notice after its ordinary shares traded below the $1.00 minimum bid price for 30 consecutive business days. The company has until November 9, 2026, to restore its bid price to at least $1.00 for 10 straight sessions, with the possibility of a second 180-day extension or actions such as a reverse stock split if needed, a situation that leaves its operations unchanged for now but introduces a compliance risk and potential delisting overhang for shareholders.
The most recent analyst rating on (ENLV) stock is a Buy with a $20.00 price target. To see the full list of analyst forecasts on Enlivex stock, see the ENLV Stock Forecast page.
Spark’s Take on ENLV Stock
According to Spark, TipRanks’ AI Analyst, ENLV is a Neutral.
The score is primarily constrained by weak financial performance—minimal revenue, ongoing operating losses, and continued cash burn—despite low leverage. Technicals also weigh on the rating as the stock trades below major moving averages with negative MACD. Valuation appears optically cheap due to the very low P/E, but that support is limited given questions about the sustainability of the reported earnings.
To see Spark’s full report on ENLV stock, click here.
More about Enlivex
Enlivex Ltd. is a quality longevity company listed on Nasdaq and based in Nes-Ziona, Israel. It is developing Allocetra™, a clinical-stage immunotherapy targeting inflammatory conditions associated with aging, with an initial focus on age-related osteoarthritis, while also running a prediction markets treasury strategy centered on the RAIN token of the Rain protocol on Arbitrum.
This dual approach aims to pair development of longevity therapeutics with financial exposure to the emerging decentralized prediction markets ecosystem. The company’s strategy positions it at the intersection of biotech and digital assets, seeking to leverage both clinical innovation and crypto-native treasury management to create shareholder value.
On May 15, 2026, Enlivex disclosed that it had received a Nasdaq notice stating its shares failed to meet the $1.00 minimum bid price requirement over the prior 30 consecutive business days. The company now has an initial 180-day grace period, until November 9, 2026, to lift its closing bid price to at least $1.00 for 10 consecutive business days and thereby regain compliance.
If Enlivex does not regain compliance by November 9, 2026, it may qualify for a second 180-day compliance window, potentially requiring measures such as a reverse stock split, or it could ultimately face delisting proceedings, with appeal rights. The notification does not immediately affect the listing or trading of Enlivex’s ordinary shares or its ongoing business operations, but it underscores market pressure on the stock and raises a near-term compliance overhang for investors.
Average Trading Volume: 544,890
Technical Sentiment Signal: Sell
Current Market Cap: $173.8M
See more insights into ENLV stock on TipRanks’ Stock Analysis page.